Overview

A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
To assess steady state pharmacokinetics (PK), safety and tolerability between AVP-786 (deuterated [d6] dextromethorphan hydrobromide [DM]/quinidine sulfate [Q]) and paroxetine and between AVP-786 and duloxetine.
Phase:
Phase 1
Details
Lead Sponsor:
Avanir Pharmaceuticals
Treatments:
Dextromethorphan
Duloxetine Hydrochloride
Paroxetine
Quinidine